稳定期慢阻肺的药物治疗:精准医学与争议
本综述围绕稳定期慢性阻塞性肺疾病(COPD)的药物治疗,重点讨论基于临床与生物标志物的个体化治疗进展,包括血嗜酸性粒细胞计数指导吸入糖皮质激素(ICS)使用,以及双联/三联吸入联合治疗的关键随机对照试验证据,并梳理当前推荐依据与争议问题。
要点
- 血嗜酸性粒细胞计数可用于预测COPD患者对ICS的应答,已进入临床实践。
- 含长效支气管扩张剂的双联/三联吸入联合治疗已有 landmark RCT 证据指导选择。
- COPD药物治疗趋向精准医学,整合临床与生物标志物信息优化个体决策。
核心结论
- COPD药物治疗旨在缓解症状并降低急性加重、疾病进展和死亡等未来风险。
- COPD异质性导致药物干预反应不一,治疗已向整合临床与生物标志物的精准医学 approach 演进。
研究设计与样本
- 综述文章,检索范围未在摘要中报告。
主要发现
- 支持血嗜酸性粒细胞计数预测COPD患者对ICS应答的证据已促使该生物标志物用于临床实践。
- 含长效支气管扩张剂联合或不联合ICS的新型双联和三联吸入联合治疗已通过若干 landmark 随机对照试验在COPD患者中评估。
- 这些研究为不同类别联合治疗的使用提供了有价值证据,但仍存在未解决问题和争论。
临床怎么用
- 可根据血嗜酸性粒细胞计数等生物标志物辅助判断COPD患者是否从ICS治疗中获益。
- 双联或三联吸入联合治疗的选择应参考相关 landmark RCT 证据及患者个体特征。
局限性
- 摘要未报告综述的检索范围、纳入研究数量及偏倚评估方法。
- 文中指出COPD药物治疗仍存在未解决问题和争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacological treatment for chronic obstructive pulmonary disease (COPD) aims to alleviate symptoms and reduce the future risk of events such as exacerbations, disease progression and death. The heterogeneity of COPD results in variable responses to pharmacological interventions. COPD treatment has evolved towards a precision medicine approach, integrating clinical and biomarker information in order to optimize treatment decisions for each individual. The evidence supporting the use of blood eosinophil counts to predict responses to inhaled corticosteroids (ICS) in COPD patients has led to the adoption of this biomarker for use in clinical practice. The development of novel double and triple inhaled combination treatments containing long-acting bronchodilators with or without ICS has involved some landmark randomized controlled trials in COPD patients. These studies have provided valuable evidence to direct the use of different classes of combination treatments. However, there are still some unresolved questions and debates. This review article describes the advances in the pharmacological treatment of COPD, particularly the personalization of treatment. The evidence base for current recommendations is discussed, and controversial issues are dissected.
引用
- Singh D. Pharmacological treatment of stable chronic obstructive pulmonary disease. Respirology. 2021. PMID: 33829619. doi:10.1111/resp.14046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。